LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

Technological advancements can address the formulation and dissolution challenges of HPMC polymers. Editor’s Note: A version of this article was published in Pharmaceutical Technology Europe’s APIs, ...

One of the challenges in cancer research is improving the delivery of chemo drugs to enhance their efficacy while decreasing the risk of side effects. Scientists now perform a theoretical prediction ...

Homogeneous molecular catalysts are highly active and selective as they possess well-tailored structures and accessible sites. Unfortunately, the difficulty related to catalyst recovery impedes their ...

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “We have completed another study that proves exactly what we expected to find in the data. Like previous biocompatibility studies on ...